REGULATION OF TISSUE FACTOR PATHWAY INHIBITOR EXPRESSION

组织因子途径抑制剂表达的调节

基本信息

  • 批准号:
    6181932
  • 负责人:
  • 金额:
    $ 10.58万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1996
  • 资助国家:
    美国
  • 起止时间:
    1996-07-01 至 2001-06-30
  • 项目状态:
    已结题

项目摘要

The primary goal of these studies is to investigate the regulation of inducible tissue factor pathway inhibitor (TFPI) gene expression in monocytes and fibroblasts. Using Northern blotting analysis and TEPI assays, the applicant had previously demonstrated that endothelium is the primary physiologic site of TFPI synthesis and that monocytes and fibroblasts normally express none to very little TFPI. However, the applicant's preliminary data indicate that TFPI expression is vastly upregulated in adherent monocytes and monocytic U93 cells. In this proposal, the applicant will define the adhesion response elements in the TFPI gene that upregulate TFPI expression in monocytes and U937 cells. The applicant has also found that fibroblasts significantly upregulate TFPI expression in response to serum and in this proposal she plans to define the serum response elements that upregulate its expression in fibroblasts. preliminary data also suggest that adherent monocytes and U937 cells, serum-stimulated fibroblasts and several transformed cell lines that express TFPI also express GATA-2 transcription factor. In gel mobility shift assays, factor(s) from nuclear extracts of HepG2 cells (a transformed cell line that expresses both TFPI and GATA-2 transcription factor) appear to bind to a DNA fragment from the TFPI promoter region containing a putative GATA motif. Additionally, GATA-2 transcription factor antisense oligomers significantly decreased the expression of TFPI and GATA-2 transcription factor mRNA in adherent UJ937 cells. Thus GATA-2 transcription factor may be required for TFPI gene expression. This possibility will be further tested in monocytes and fibroblasts by the use of sense and antisense strategies. Preliminary data was generated under the guidance of the sponsor, Paul Bajaj, who is an expert ina the field of coagulation and thrombosis. The applicant will continue to work in the laboratory of Paul Bajaj for the proposed studies. She will also receive constant guidance from the co- sponsor, Joel Eissenberg who is an experienced and recognized molecular biologist. The applicant will meet frequently with the advisory committee (Drs. Sly, Huang, Hyers, and Payvar) to seek guidance and discuss her progress. Thus ample resources and vast expertise is available to the applicant to perform the proposed studies. It is anticipated that the studies will yield important new information on the regulation of inducible TEPI gene expression during an inflammatory response.
这些研究的主要目标是调查 诱导型组织因子途径抑制剂 (TFPI) 基因表达 单核细胞和成纤维细胞。 使用 Northern 印迹分析和 TEPI 化验,申请人之前已证明内皮细胞是 TFPI 合成的主要生理部位以及单核细胞和 成纤维细胞通常不表达或表达很少的 TFPI。 然而, 申请人的初步数据表明,TFPI表达量极大 在贴壁单核细胞和单核 U93 细胞中上调。 在这个 提案中,申请人将在 TFPI 基因上调单核细胞和 U937 细胞中的 TFPI 表达。 这 申请人还发现成纤维细胞显着上调 TFPI 对血清的反应表达,在本提案中,她计划定义 上调其在成纤维细胞中表达的血清反应元件。 初步数据还表明贴壁单核细胞和 U937 细胞, 血清刺激的成纤维细胞和几种转化细胞系 表达TFPI也表达GATA-2转录因子。 凝胶流动性 移位分析,来自 HepG2 细胞核提取物的因子(转化的 同时表达 TFPI 和 GATA-2 转录因子的细胞系)出现 结合 TFPI 启动子区域的 DNA 片段,其中包含 假定的 GATA 主题。 此外,GATA-2 转录因子反义 寡聚物显着降低 TFPI 和 GATA-2 的表达 贴壁 UJ937 细胞中的转录因子 mRNA。 因此GATA-2 TFPI 基因表达可能需要转录因子。 这 将通过使用在单核细胞和成纤维细胞中进一步测试可能性 有义和反义策略。 初步数据是在赞助商 Paul 的指导下生成的 Bajaj是凝血和血栓领域的专家。 这 申请人将继续在Paul Bajaj的实验室工作 拟议的研究。 她还将得到同事的持续指导 赞助商 Joel Eissenberg 是一位经验丰富且公认的分子 生物学家。 申请人将经常与顾问委员会会面 (Sly 博士、Huang 博士、Hyers 博士和 Payvar 博士)寻求指导并讨论她 进步。 因此,充足的资源和丰富的专业知识可供 申请人进行拟议的研究。 预计 研究将产生有关诱导调节的重要新信息 炎症反应期间 TEPI 基因的表达。

项目成果

期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Role of GATA motifs in tissue factor pathway inhibitor gene expression in malignant cells.
GATA 基序在恶性细胞组织因子途径抑制剂基因表达中的作用。
  • DOI:
    10.1016/s0049-3848(00)00393-5
  • 发表时间:
    2001
  • 期刊:
  • 影响因子:
    7.5
  • 作者:
    Bajaj,MS;Tyson,DR;Steer,SA;Kuppuswamy,MN
  • 通讯作者:
    Kuppuswamy,MN
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Madhu Satya Bajaj其他文献

Madhu Satya Bajaj的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Madhu Satya Bajaj', 18)}}的其他基金

Efficacy of Kunitz Domain 1 variants of TFPI-2 as novel antifibrinolytic agents
TFPI-2 Kunitz 结构域 1 变体作为新型抗纤维蛋白溶解剂的功效
  • 批准号:
    7589884
  • 财政年份:
    2009
  • 资助金额:
    $ 10.58万
  • 项目类别:
Efficacy of Kunitz Domain 1 variants of TFPI-2 as novel antifibrinolytic agents
TFPI-2 Kunitz 结构域 1 变体作为新型抗纤维蛋白溶解剂的功效
  • 批准号:
    7792289
  • 财政年份:
    2009
  • 资助金额:
    $ 10.58万
  • 项目类别:
REGULATION OF TISSUE FACTOR PATHWAY INHIBITOR EXPRESSION
组织因子途径抑制剂表达的调节
  • 批准号:
    2211397
  • 财政年份:
    1996
  • 资助金额:
    $ 10.58万
  • 项目类别:
REGULATION OF TISSUE FACTOR PATHWAY INHIBITOR EXPRESSION
组织因子途径抑制剂表达的调节
  • 批准号:
    6030356
  • 财政年份:
    1996
  • 资助金额:
    $ 10.58万
  • 项目类别:
REGULATION OF TISSUE FACTOR PATHWAY INHIBITOR EXPRESSION
组织因子途径抑制剂表达的调节
  • 批准号:
    2445017
  • 财政年份:
    1996
  • 资助金额:
    $ 10.58万
  • 项目类别:
REGULATION OF TISSUE FACTOR PATHWAY INHIBITOR EXPRESSION
组织因子途径抑制剂表达的调节
  • 批准号:
    2734937
  • 财政年份:
    1996
  • 资助金额:
    $ 10.58万
  • 项目类别:

相似海外基金

Development of a method for preserving transplanted lung function using Gapmer-type antisense nucleic acid
开发利用Gapmer型反义核酸保存移植肺功能的方法
  • 批准号:
    22K09003
  • 财政年份:
    2022
  • 资助金额:
    $ 10.58万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Myostatin antisense nucleic acid therapy for rhabdomyosarcoma
肌肉生长抑制素反义核酸治疗横纹肌肉瘤
  • 批准号:
    21K07762
  • 财政年份:
    2021
  • 资助金额:
    $ 10.58万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Suppression of PHOX2B (+7Ala mutant) expression by antisense nucleic acid
反义核酸抑制 PHOX2B(7Ala 突变体)表达
  • 批准号:
    20K16927
  • 财政年份:
    2020
  • 资助金额:
    $ 10.58万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Pathogenesis and Antisense nucleic acid, glycosylation supplementation, and AAV therapy development forFukuyama muscular dystrophy and related diseases
福山性肌营养不良症及相关疾病的发病机制和反义核酸、糖基化补充以及 AAV 疗法的开发
  • 批准号:
    20H00526
  • 财政年份:
    2020
  • 资助金额:
    $ 10.58万
  • 项目类别:
    Grant-in-Aid for Scientific Research (A)
Synthesis of antisense nucleic acid incorporating cyclic sulfonamide backbone
掺入环状磺酰胺主链的反义核酸的合成
  • 批准号:
    20K21245
  • 财政年份:
    2020
  • 资助金额:
    $ 10.58万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
Antisense nucleic acid splice correction therapy for Duchenne muscular dystrophy and related disorders
杜氏肌营养不良症及相关疾病的反义核酸剪接校正疗法
  • 批准号:
    G0900887/1
  • 财政年份:
    2011
  • 资助金额:
    $ 10.58万
  • 项目类别:
    Research Grant
CHEMICAL SYNTHESIS OF A NEW MATERIAL OF ANTISENSE NUCLEIC ACID "2'-PHOSPHORYLATED RNAS" -DIRECTED TOWARD ITS BASIC STRUCTURAL STUDIES AND REGULATION OF EXPRESSION OF HIV VIRUS-
反义核酸新材料“2-磷酸化RNAS”的化学合成-针对其基础结构研究和HIV病毒表达调控-
  • 批准号:
    05558090
  • 财政年份:
    1993
  • 资助金额:
    $ 10.58万
  • 项目类别:
    Grant-in-Aid for Developmental Scientific Research (B)
CHEMICAL SYNTHESIS OF A NEW MATERIAL OF ANTISENSE NUCLEIC ACID"2"PHOSTHORYLATEDRNAS" DIRETED TOWARD IIS BASIC STRUCTRAL STUDIES AND REGULATION OF EXPRESSION OF HIV VIRUS-
针对 IIS 基础结构研究和 HIV 病毒表达调控的反义核酸新材料“2”磷酸化 RNA 的化学合成-
  • 批准号:
    04453031
  • 财政年份:
    1992
  • 资助金额:
    $ 10.58万
  • 项目类别:
    Grant-in-Aid for General Scientific Research (B)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了